Bimzelx (bimekizumab-bkzx) / UCB, BRL Medicine - LARVOL DELTA

Response to bimekizumab in a patient with generalized pustular psoriasis who developed secondary failure. (PubMed, Eur J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Indirect Comparison Between Bimekizumab And Brodalumab For The Management Of Moderate To Severe Psoriasis: A 36-Week Real-Life Study (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A

Efficacy and survival probability of patients with psoriasis treated with IL-17 inhibitors - bimekizumab, brodalumab, ixekizumab, and secukinumab: Real-world data from the Czech Republic BIOREP registry (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology-Rheumatology Clinic: A 24-Week Multicenter Study. (PubMed, Rheumatol Ther) - "BKZ demonstrated rapid and sustained improvements in PsA symptoms in a challenging real-world population, with a favorable safety profile."

Clinical • Journal • Real-world evidence • Candidiasis • Dermatology • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Biologic therapies and small molecules in the treatment of hidradenitis suppurativa. (PubMed, Clin Dermatol) - "Currently, the only three approved biologics for HS are the anti-tumor necrosis factor alpha (anti-TNF-α) antibody adalimumab, the anti-interleukin-17A (anti-IL-17A) secukinumab, and the anti-IL-17A or 17F, bimekizumab. Research in the field of HS is rapidly evolving, with a wide range of treatments being developed that leverage various mechanisms of action. Drugs targeting the IL-17 and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways show promise in ongoing and completed phase 3 studies, offering the potential for more comprehensive treatment responses."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • IL17A

BE UNIQUE: A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: UCB Biopharma SRL | Trial primary completion date: Apr 2026 ➔ Mar 2027

Biomarker • Trial primary completion date • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Bimekizumab response in the nail matrix and nail bed through 3 years in patients with moderate to severe plaque psoriasis (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Rapid response to bimekizumab for psoriasis and seborrheic dermatitis (EADV 2025) - No abstract available

Dermatitis • Dermatology • Immunology • Psoriasis • Seborrheic Dermatitis

Bimekizumab efficacy and safety in Chinese patients with moderate to severe plaque psoriasis in the BE SHINING phase 3, multicentre, randomised, double-blinded, placebo-controlled study (EADV 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

Bimekizumab treatment in psoriasis patients who failed other biological treatment: A 104-week real-life study (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease (EADV 2025) - No abstract available

Gene Signature • Cardiovascular • Immunology • Inflammation

Bimekizumab safety in patients with psoriasis achieving complete skin clearance: 4-year analysis from 5 phase 3/3b trials (EADV 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

Clinical effectiveness of bimekizumab in recalcitrant and difficult-to-treat psoriasis areas (scalp, genital, nails and palmoplantar sites): a prospective observational study in real-life clinical practice. (EADV 2025) - No abstract available

Clinical • Observational data • Dermatology • Immunology • Psoriasis

Bimekizumab remission and high disease control over 4 years in patients with psoriasis achieving complete skin clearance at Week 16: Results from four phase 3 trials (EADV 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

Bimekizumab long-term incidence of psoriatic arthritis symptoms and psoriatic arthritis adverse events in patients with psoriasis and risk factors for disease progression (EADV 2025) - No abstract available

Adverse events • Clinical • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Effectiveness, safety and drug survival of bimekizumab by BMI category in patients with moderate-to-severe plaque psoriasis (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Clinical evolution and quality of life in patients with plaque psoriasis treated with bimekizumab: early response analysis and associated factors (EADV 2025) - No abstract available

Clinical • HEOR • Dermatology • Immunology • Psoriasis

The role of ultra-high frequency ultrasound for the assessment and monitoring of nail psoriasis in patients treated with bimekizumab (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension (EADV 2025) - No abstract available

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Effective treatment of psoriasis vulgaris and hidradenitis suppurativa with bimekizumab in a patient with HIV after treatment failure with adalimumab and secukinumab (EADV 2025) - No abstract available

Clinical • Dermatology • Hidradenitis Suppurativa • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Systematic Review and Meta Analysis of RCTs (EADV 2025) - No abstract available

Retrospective data • Review • Dermatology • Hidradenitis Suppurativa • Immunology

Efficacy and Safety of Two IL-17 Inhibitors (Bimekizumab and Secukinumab) in the Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) (EADV 2025) - No abstract available

Retrospective data • Review • Dermatology • Hidradenitis Suppurativa • Immunology • IL17A

Exacerbation of Psoriatic Lesions and Vascular Complications in a Patient Treated with Bimekizumab: A Case Report (EADV 2025) - No abstract available

Case report • Clinical • Immunology • Psoriasis

Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study (EADV 2025) - No abstract available

Clinical • Head-to-Head • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A